×
About 3,585 results

ALLMedicine™ Epistaxis Center

Research & Reviews  1,140 results

ACR Appropriateness Criteria® Imaging of Facial Trauma Following Primary Survey.
https://doi.org/10.1016/j.jacr.2022.02.013
Journal of the American College of Radiology : JACR; , Parsons MS et. al.

May 14th, 2022 - Maxillofacial trauma patients comprise a significant subset of patients presenting to emergency departments. Before evaluating for facial trauma, an emergency or trauma physician must perform a primary survey to ensure patient stabilization. Follo...

A retrospective review of spontaneous epistaxis outcomes for patients on novel oral ant...
https://doi.org/10.1016/j.amjoto.2022.103488
American Journal of Otolaryngology; Maina G, Ooi E

May 11th, 2022 - The incidence of epistaxis-related admissions amongst elderly patients is rising due to the increasing use of anticoagulants and antiplatelet agents. This retrospective study evaluates the differences in outcomes for patients on warfarin, novel an...

Skull Base Regeneration During Treatment With Chemoradiation for Nasopharyngeal Carcinoma: A Case Report
https://www.mdedge.com/fedprac/avaho/article/254501/head-neck/thyroid-cancers/skull-base-regeneration-during-treatment
Kelly F. Moyer, MD, Jessica H. Maxwell, MD, MPH et. al.

May 10th, 2022 - Nasopharyngeal carcinoma (NPC) differs from other head and neck (H&N) cancers in its epidemiology and treatment. Unlike other H&N cancers, NPC has a distinct geographical distribution with a much higher incidence in endemic areas, such as southern.

Endovascular coiling of recurrent trapped pseudoaneurysm of petrous ICA across the dist...
https://doi.org/10.1177/19714009221096835
The Neuroradiology Journal; Hosur B, Ahuja CK et. al.

May 3rd, 2022 - The pseudoaneurysms of the internal carotid artery (ICA) at the skull base form a unique subset of craniofacial pseudoaneurysms with varied diagnostic and therapeutic challenges. Recurrence in a surgically treated pseudoaneurysm may become a night...

Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis...
https://doi.org/10.1016/j.gie.2022.02.044
Gastrointestinal Endoscopy; Boland CR, Idos GE et. al.

Apr 30th, 2022 - The gastrointestinal hamartomatous polyposis syndromes are rare, autosomal dominant disorders associated with an increased risk of benign and malignant intestinal and extraintestinal tumors. They include Peutz-Jeghers syndrome, juvenile polyposis ...

see more →

Guidelines  4 results

ACR Appropriateness Criteria® Imaging of Facial Trauma Following Primary Survey.
https://doi.org/10.1016/j.jacr.2022.02.013
Journal of the American College of Radiology : JACR; , Parsons MS et. al.

May 14th, 2022 - Maxillofacial trauma patients comprise a significant subset of patients presenting to emergency departments. Before evaluating for facial trauma, an emergency or trauma physician must perform a primary survey to ensure patient stabilization. Follo...

Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis...
https://doi.org/10.1016/j.gie.2022.02.044
Gastrointestinal Endoscopy; Boland CR, Idos GE et. al.

Apr 30th, 2022 - The gastrointestinal hamartomatous polyposis syndromes are rare, autosomal dominant disorders associated with an increased risk of benign and malignant intestinal and extraintestinal tumors. They include Peutz-Jeghers syndrome, juvenile polyposis ...

Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis...
https://doi.org/10.1053/j.gastro.2022.02.021
Gastroenterology Boland CR, Idos GE et. al.

Apr 30th, 2022 - The gastrointestinal hamartomatous polyposis syndromes are rare, autosomal dominant disorders associated with an increased risk of benign and malignant intestinal and extraintestinal tumors. They include Peutz-Jeghers syndrome, juvenile polyposis ...

Clinical Practice Guideline: Nosebleed (Epistaxis).
https://doi.org/10.1177/0194599819890327
Otolaryngology--head and Neck Surgery : Official Journal ... Tunkel DE, Anne S et. al.

Jan 8th, 2020 - Nosebleed, also known as epistaxis, is a common problem that occurs at some point in at least 60% of people in the United States. While the majority of nosebleeds are limited in severity and duration, about 6% of people who experience nosebleeds w...

see more →

Drugs  165 results see all →

Clinicaltrials.gov  35 results

Xylometazoline and Cocaine for Nasal Vasoconstriction
https://clinicaltrials.gov/ct2/show/NCT05334017

Apr 27th, 2022 - When performed by trained personnel nasotracheal intubation is a safe and effective technique for attaining a secure airway in preparation for surgery of the head and neck. Upon intubation the nasal mucosa must be sufficiently lubricated and decon...

Post-operative Pain Control With Acetaminophen and Ibuprofen After Functional Endoscopic Sinus Surgery
https://clinicaltrials.gov/ct2/show/NCT05287217

Apr 7th, 2022 - The safest and most effective post-operative pain control regimen after functional endoscopic sinus surgery (FESS) has been the subject of persistent debate and research for many years. The main reasons for this debate is due to two factors: 1) en...

Pomalidomide for the Treatment of Bleeding in HHT
https://clinicaltrials.gov/ct2/show/NCT03910244

Mar 21st, 2022 - HHT is associated with substantial morbidity, leading to a reduced quality of life, decreased rate of employment and a high incidence of depression. There currently exists no medical therapy recognized as consistently efficacious in HHT. Reports o...

Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.
https://clinicaltrials.gov/ct2/show/NCT03954782

Mar 17th, 2022 - The recognized manifestations of HHT are all due to abnormalities in vascular structure. Epistaxis are spontaneous, very variable, may occur as often as several times every day, and are recurrent in 90% of patients and associated with chronic and ...

Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient
https://clinicaltrials.gov/ct2/show/NCT04108052

Oct 19th, 2021 - Hereditary hemorrhagic telangiectasia (HHT) is linked to a dysregulation of angiogenesis leading to the formation of arteriovenous malformations (AVM): cutaneo-mucous telangiectasia and visceral shunts. The diagnosis is clinical and based on Curaç...

see more →

News  89 results

Skull Base Regeneration During Treatment With Chemoradiation for Nasopharyngeal Carcinoma: A Case Report
https://www.mdedge.com/fedprac/avaho/article/254501/head-neck/thyroid-cancers/skull-base-regeneration-during-treatment
Kelly F. Moyer, MD, Jessica H. Maxwell, MD, MPH et. al.

May 10th, 2022 - Nasopharyngeal carcinoma (NPC) differs from other head and neck (H&N) cancers in its epidemiology and treatment. Unlike other H&N cancers, NPC has a distinct geographical distribution with a much higher incidence in endemic areas, such as southern.

Ceralasertib Plus Acalabrutinib Shows Early Activity in High-Risk Relapsed/Refractory CLL
https://www.onclive.com/view/ceralasertib-plus-acalabrutinib-shows-early-activity-in-high-risk-relapsed-refractory-cll

Apr 29th, 2022 - The combination of ceralasertib (AZD6738) and acalabrutinib (Calquence) showed preliminary clinical activity with acceptable tolerability in patients with high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), according to data from a ...

FDA Grants Fast Track Status to HPN217 for Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/fda-grants-fast-track-status-to-hpn217-for-relapsed-refractory-multiple-myeloma

Mar 3rd, 2022 - The FDA has granted a fast track designation to the BCMA-targeting Tri-specific T-cell Activating Construct (TriTAC), HPN217, for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who have previously re...

Cervical Cancer Treatment Paradigm Is Bolstered With Newly Approved Therapies
https://www.onclive.com/view/cervical-cancer-treatment-paradigm-is-bolstered-with-newly-approved-therapies

Jan 28th, 2022 - Treatment of patients with metastatic cervical cancer remains challenging—the 5-year overall survival (OS) rate is just 17%.1 Whereas many other solid tumors have seen a plethora of FDA approvals of clinically meaningful treatments, there has been...

FDA Grants Priority Review to Beti-Cel for β-thalassemia Requiring Transfusions
https://www.onclive.com/view/fda-grants-priority-review-to-beti-cel-for--thalassemia-requiring-transfusions

Nov 22nd, 2021 - The FDA has granted a priority review designation to a biologics license application (BLA) for betibeglogene autotemcel (beti-cel) for the treatment of adult, adolescent, and pediatric patients with β-thalassemia across all genotypes who require r...

see more →

Patient Education  1 results see all →